World Health Organization Raises Alert Over Critical Lack of Weight-Loss Jabs
Less than one in 10 patients eligible to benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it releases its initial guidance on the medications.
Given more than one billion people worldwide currently obese, it is calling for more widespread and fairer availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The new guidelines recognises that excess weight is a lifelong illness that can be managed with thorough and lifelong support," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major obstacles to widespread access to the injections that can aid individuals in losing considerable body mass, notes the organization.
GLP-1 Therapy Scarcity
Even in the current best projected outlook, the production of these medications could only cover about 100 million people – under 10% of the global need, according to the health organization.
The advice urges nations and manufacturers to widen availability, via approaches such as licensing agreements.
A patent on semaglutide – the main component of the drug Wegovy – is set to lapse in several nations in 2026.
The Way Obesity Injections Work
The injections imitate a body's own hormone to delay gastric emptying, suppress the appetite and enhance satiety so users consume fewer calories.
Patients usually begin shedding pounds in the initial weeks of beginning the regular doses.
Research suggests patients may put most of the weight back on after a year of stopping the drug, when their normal appetite return.
Being above a healthy weight raises your likelihood for developing diseases, like diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns individuals in every country and was responsible for millions of deaths worldwide in 2024, according to the WHO.
